HIF1A and depressive symptom measurement: We next inhibited HIF-1α and NLRP3 by intra-thalamic injection of YC-1 (HIF-1α inhibitor) and MCC950 (NLRP3 inhibitor) and assessed mechanical pain sensitivity and anxiety- and depression-like behaviors (Fig. 4A).